Evidence map›Paper›PMID 38523341›Full record

Trial reportCardiovascular research2024

Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.

Christopher J Farina, Michael H Davidson, Prediman K Shah, Charles Stark, Wenqi Lu, Cheerag Shirodaria, Timothy Wright, Charalambos A Antoniades, Jan Nilsson, Nehal N Mehta

Open access · hybridAbstract readRandomized Controlled TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Review
  7. Review
  8. From Bench to Clinic: Advances in Anti-Inflammatory Therapies for Atherosclerotic Coronary Artery Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Tipping the Scale: Atheroprotective IgM-Producing B Cells in Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  16. Inflammation and Atherosclerosis: Prospects for Clinical Trials.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Christopher J FarinaAbcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.
Michael H DavidsonDepartment of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
Prediman K ShahDepartment of Cardiology and Smidt Heart Institute, Oppenheimer Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Charles StarkAbcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.
Wenqi LuAbcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.
Cheerag ShirodariaCaristo Diagnostics, Oxford, UK.ORCID 0000-0001-6463-1838
Timothy WrightAbcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.
Charalambos A AntoniadesRadcliffe Department of Medicine, Division of Cardiovascular Medicine, Acute Multidisciplinary Imaging and Interventional Centre, University of Oxford, UK.
Jan NilssonAbcentra, 1925 Century Park E #1700, Los Angeles, CA 90067, USA.ORCID 0000-0002-9752-7479
Nehal N MehtaSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Abcentra (United States) · USCedars-Sinai Medical Center · USMalmö University · SENational Institutes of Health · USUniversity of Chicago Medical Center · USUniversity of Oxford · GB

Funding

AbcentraBritish Heart Foundation CH/F/21/90009British Heart Foundation CH/F/21/90009 and RG/F/21/110040British Heart Foundation RG/F/21/110040NIH HHSResearch Oxford Biomedical Research Centre
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedLipoproteins, LDLPsoriasisAdultAnti-Inflammatory AgentsBiomarkersDouble-Blind MethodFemaleHumansInflammation MediatorsMaleMiddle AgedPilot ProjectsTreatment OutcomeAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsBiomarkersInflammation MediatorsLipoproteins, LDLoxidized low density lipoprotein

Identifiers

PMID38523341
PMCPMC11135636
OpenAlexW4393157069

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.